成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Cell Cycle/DNA Damage Anti-infection
  3. Antifolate Parasite
  4. Pyrimethamine

Pyrimethamine  (Synonyms: 乙胺嘧啶; Pirimecidan; Pirimetamin; RP 4753)

目錄號: HY-18062 純度: 99.99%
COA 產(chǎn)品使用指南 技術支持

Pyrimethamine (Pirimecidan) 是一種口服有效的雙氫葉酸還原酶 (DHFR) 抑制劑。Pyrimethamine 是一種抗瘧劑。Pyrimethamine 通過干擾葉酸-葉酸系統(tǒng)影響瘧原蟲的核蛋白代謝，并通過抑制二氫葉酸向四氫葉酸的轉(zhuǎn)化影響細胞分裂。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務

Pyrimethamine Chemical Structure

Pyrimethamine Chemical Structure

CAS No. : 58-14-0

1.  客戶無需承擔相應的運輸費用。

2.  同一機構（單位）同一產(chǎn)品試用裝僅限申領一次，同一機構（單位）一年內(nèi)

     可免費申領三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥790
In-stock
100 mg ￥600
In-stock
500 mg ￥1400
In-stock
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Pyrimethamine:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻

生物活性

Pyrimethamine (Pirimecidan) is a potent, orally active dihydrofolate reductase (DHFR) inhibitor. Pyrimethamine is an antimalarial agent. Pyrimethamine affects the nucleoprotein metabolism of malarial parasites by interference in the folic–folinic acid systems and affects cell division by inhibiting the conversion of dihydrofolate to tetrahydrofolate[1][2].

IC50 & Target

Plasmodium

 

細胞效力
(Cellular Effect)
Cell Line Type Value Description References
CHO IC50
271 μM
Compound: PM
Cytotoxicity against CHO cells after 48 hrs by MTT assay
Cytotoxicity against CHO cells after 48 hrs by MTT assay
[PMID: 24602791]
Erythrocyte IC50
0.004 μM
Compound: Pyrimethamine
Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay
Antimalarial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human RBC assessed as parasite growth inhibition incubated for 72 hrs by SYBR Green dye based fluorescence assay
[PMID: 36561069]
HEK293 IC50
> 10 μM
Compound: Pyrimethamine
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue dye based fluorescence assay
[PMID: 36799121]
HEK293 CC50
≥ 20 μM
Compound: Pyrimethamine
Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay
Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay
[PMID: 30537832]
HEK293 IC50
0.69 μM
Compound: Pyrimethamine
Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay
Cytotoxicity against HEK293 cells after 72 hrs by resazurin dye based assay
[PMID: 29236492]
HEK293 IC50
13.57 μM
Compound: Pyrimethamine
Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay
[PMID: 28230985]
HEK293 IC50
4.2 μM
Compound: Pyrimethamine
Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay
Growth inhibition of HEK293 cells after 72 hrs by PrestoBlue staining based fluorescence assay
[PMID: 28001067]
HEK293 IC50
4.22 nM
Compound: Pyrimethamine
Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis
Cytotoxicity against HEK293 cells assessed as cell viability after 72 hrs by resazurin-based plate reader analysis
[PMID: 26651537]
HEK293 IC50
8.07 nM
Compound: Pyrimethamine
Cytotoxicity against HEK293 cells by alamar blue assay
Cytotoxicity against HEK293 cells by alamar blue assay
[PMID: 27212070]
HEL IC50
0.67 μM
Compound: Pyrimethamine
The ability to inhibit [3H]- uracil incorporation by Toxoplasma gondii in cultures of HEL cells was tested
The ability to inhibit [3H]- uracil incorporation by Toxoplasma gondii in cultures of HEL cells was tested
[PMID: 10090784]
HEL IC50
0.7 μM
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii infected in HEL cells assessed as inhibition of parasite growth by [3H]uracil incorporation assay
Antimicrobial activity against Toxoplasma gondii infected in HEL cells assessed as inhibition of parasite growth by [3H]uracil incorporation assay
[PMID: 20117005]
HeLa EC50
> 100 μM
Compound: 32
Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
[PMID: 28477572]
HeLa EC50
> 100 μM
Compound: 32
Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
[PMID: 28477572]
HeLa EC50
0.75 μM
Compound: 32
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis
[PMID: 28477572]
HepG2 IC50
< 1 μM
Compound: Pyrimethamine
Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin
Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin
[PMID: 23927658]
HepG2 IC50
1.03 μM
Compound: 76
Antimalarial activity against liver stages of Plasmodium cynomolgi infected in human HepG2 cells assessed as growth inhibition of hepatic parasite after 3 days
Antimalarial activity against liver stages of Plasmodium cynomolgi infected in human HepG2 cells assessed as growth inhibition of hepatic parasite after 3 days
[PMID: 22122518]
HepG2 IC50
30 μM
Compound: Pyrimethamine
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 19482476]
HepG2 CC50
7.1 μM
Compound: Pyrimethamine
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 22608675]
HepG2 CC50
7.1 μM
Compound: Pyrimethamine
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 21741131]
HFF CC50
> 50 μM
Compound: Pyrimethamine
Cytotoxicity against human HFF cells after 72 hrs by MTT assay
Cytotoxicity against human HFF cells after 72 hrs by MTT assay
[PMID: 21741131]
HFF CC50
> 50 μM
Compound: Pyrimethamine
Cytotoxicity against HFF assessed as cell proliferation after 96 hrs by alamar blue reduction assay
Cytotoxicity against HFF assessed as cell proliferation after 96 hrs by alamar blue reduction assay
[PMID: 26479029]
HFF EC50
0.21 μM
Compound: Pyrimethamine
Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
Antiparasitic activity against Toxoplasma gondii ATCC 50839 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
[PMID: 17698618]
HFF EC50
0.24 μM
Compound: Pyrimethamine
Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
Antiparasitic activity against artemisinin-resistant Toxoplasma gondii STL500-10A infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
[PMID: 17698618]
HFF EC50
0.27 μM
Compound: Pyrimethamine
Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-6 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
[PMID: 17698618]
HFF EC50
0.29 μM
Compound: Pyrimethamine
Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
Antiparasitic activity against artemisinin-resistant Toxoplasma gondii KN200-1 infected in HFF cells after 72 hrs by beta-galactosidase reporter gene assay
[PMID: 17698618]
HFF IC50
0.8 μM
Compound: Pyrimethamine
Antitoxoplasmic activity against Toxoplasma gondii PRU tachyzoites infected in human HFF cells assessed as beta-galactosidase activity after 72 hrs by colorimetric assay
Antitoxoplasmic activity against Toxoplasma gondii PRU tachyzoites infected in human HFF cells assessed as beta-galactosidase activity after 72 hrs by colorimetric assay
[PMID: 22608675]
HFF IC50
1.1 μM
Compound: Pyrimethamine
Antiparasitic activity against Toxoplasma gondii PRU tachyzoites harboring beta-Gal gene infected in human HFF cells after 72 hrs by microtiter plate based assay
Antiparasitic activity against Toxoplasma gondii PRU tachyzoites harboring beta-Gal gene infected in human HFF cells after 72 hrs by microtiter plate based assay
[PMID: 21741131]
K562 IC50
5 μM
Compound: Pyrimethamine
Cytotoxicity against human K562 cells after 72 hrs by flow cytometry
Cytotoxicity against human K562 cells after 72 hrs by flow cytometry
[PMID: 19482476]
MCF7 EC50
11700 nM
Compound: 1
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
[PMID: 30624926]
MCF7 IC50
453 μM
Compound: PYM
Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay
Antiproliferative activity in human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTS assay
[PMID: 32061484]
MDA-MB-231 IC50
238 μM
Compound: PYM
Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay
Antiproliferative activity in human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTS assay
[PMID: 32061484]
MDCK CC50
41 μM
Compound: 32
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay
[PMID: 28477572]
MRC5 IC50
0.07 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.09 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.09 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.1 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.11 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.11 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.12 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.14 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.15 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.17 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.18 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.19 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.25 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.34 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.35 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 IC50
0.39 mg/L
Compound: Pyrimethamine
Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA
Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA
[PMID: 18212105]
MRC5 ED50
16.23 μg/mL
Compound: 1
Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay
Cytotoxicity against human MRC5 cells after 72 hrs by Alamar blue assay
[PMID: 21126022]
Vero IC50
> 6.25 μg/mL
Compound: Pyrimethamine
Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against monkey Vero cells assessed as decrease in cell viability after 72 hrs by MTT assay
[PMID: 28552337]
Vero IC50
> 62.5 μg/mL
Compound: Pyrimethamine
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay
[PMID: 23352268]
Vero CC50
122 μM
Compound: Pyr
Cytotoxicity against African green monkey Vero cells after 24 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells after 24 hrs by MTT assay
[PMID: 25899334]
Vero IC50
18.2 μM
Compound: 2
Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay
Cytotoxicity against african green monkey Vero cells after 48 hrs by neutral red assay
[PMID: 24900509]
Vero IC50
32 μM
Compound: PYR
Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay
Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay
[PMID: 31685330]
Vero IC50
32 μM
Compound: Pyr
Cytotoxicity by the selective inhibition against African green monkey kidney fibroblast (vero cells).
Cytotoxicity by the selective inhibition against African green monkey kidney fibroblast (vero cells).
[PMID: 11881993]
體外研究
(In Vitro)

Pyrimethamine (Pirimecidan; 4 nM-4 μM; 24 h; LLC-MK2 cells with T. gondii) combination of Fluconazole (FLZ) (HY-B0101) inhibits T. gondii activity with IC50 values of 0.23, 0.19, 0.23, 0.34, 0.14, and 0.19 μM for FLZ concentration at 0, 0.05, 0.1, 0.5, 1.0, and 3.0 μM, respectively[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: LLC-MK2 cells with T. gondii
Concentration: 4 nM-4 μM
Incubation Time: 24 hours
Result: Inhibited T. gondii activity and decreased parasite proliferation index.
體內(nèi)研究
(In Vivo)

Pyrimethamine (Pirimecidan; 1 mg/kg; i.g.; daily, for 10 d; female CF1 mice with T. gondii xenograft) combination of Fluconazole (HY-B0101) and Sulfadiazine (HY-B0273) increases protection from death[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CF1 mice (18-22 g; 4-6 week of age) with T. gondii xenograft[1]
Dosage: Oral gavage; daily, for 10 days
Administration: 1 mg/kg; 10 mg/kg (Fluconazole (HY-B0101)), 40 mg/kg (Sulfadiazine (HY-B0273))
Result: Increased mouse survival compared to treatment with SDZ/PYR alone.
Clinical Trial
分子量

248.71

Formula

C12H13ClN4
CAS 號
性狀

固體

顏色

White to off-white

中文名稱

乙胺嘧啶；乙嘧啶；息瘧定；達拉匹林
運輸條件

Room temperature in continental US; may vary elsewhere.
儲存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性數(shù)據(jù)
細胞實驗： 

DMSO 中的溶解度 : 20 mg/mL (80.41 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 4.0207 mL 20.1037 mL 40.2075 mL
5 mM 0.8041 mL 4.0207 mL 8.0415 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗：

請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (10.05 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑： 10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (10.05 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液，此方案實驗周期在半個月以上的動物實驗酌情使用。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請依序添加每種溶劑： 50% PEG300    50% PBS

    Solubility: 25 mg/mL (100.52 mM); 懸濁液; 超聲助溶

動物溶解方案計算器
請輸入動物實驗的基本信息：

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

只
由于實驗過程有損耗，建議您多配一只動物的量
請輸入您的動物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購。 ，Tween 80，均可在 MCE 網(wǎng)站選購。
計算結(jié)果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲備液濃度超過該產(chǎn)品的實測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術支持聯(lián)系。
動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上，請謹慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.99%

參考文獻

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲存時，請在2年內(nèi)使用， -20°C儲存時，請在1年內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 4.0207 mL 20.1037 mL 40.2075 mL 100.5187 mL
5 mM 0.8041 mL 4.0207 mL 8.0415 mL 20.1037 mL
10 mM 0.4021 mL 2.0104 mL 4.0207 mL 10.0519 mL
15 mM 0.2680 mL 1.3402 mL 2.6805 mL 6.7012 mL
20 mM 0.2010 mL 1.0052 mL 2.0104 mL 5.0259 mL
25 mM 0.1608 mL 0.8041 mL 1.6083 mL 4.0207 mL
30 mM 0.1340 mL 0.6701 mL 1.3402 mL 3.3506 mL
40 mM 0.1005 mL 0.5026 mL 1.0052 mL 2.5130 mL
50 mM 0.0804 mL 0.4021 mL 0.8041 mL 2.0104 mL
60 mM 0.0670 mL 0.3351 mL 0.6701 mL 1.6753 mL
80 mM 0.0503 mL 0.2513 mL 0.5026 mL 1.2565 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機構名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Pyrimethamine
目錄號：
HY-18062
需求量：